Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Timothy F. Burns

First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A First-In-Class TWIST1 Inhibitor With Activity in Oncogene-Driven Lung Cancer

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2017English

Related publications

P2.13-23 Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients With EGFR T790m-Positive NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA15.10 Loss of T790M Mutation Is Associated With Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy